Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1037-1049, December 2007

Mixed connective tissue disease: what is behind the curtain?

  • Martin Aringer, MD (Chief)

      Affiliations

    • Corresponding Author InformationCorresponding author. Professor of Medicine, Division of Rheumatology, Department of Medicine III, University Clinical Center Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany. Tel.: +49 351 458 4422; Fax: +49 351 458 5801.

Division of Rheumatology, Department of Medicine III, University Center Carl Gustav Carus, Technical University of Dresden, Germany

Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria

Although there is still an emotional debate over the existence of mixed connective tissue disease, the evidence from animal models suggests that anti-U1RNP antibodies, similar to other autoantibodies in other connective tissue diseases (such as antisynthetase, anticentromere, and antitopoisomerase), play a pathophysiological role in this disease. Despite an antiendothelial effect of anti-U1RNP antibodies, which is reminiscent of anticentromere antibodies, patients with high-titer autoantibodies to U1RNP in the absence of anti-Sm antibodies do not usually have or develop typical systemic sclerosis. Instead, their severe Raynaud's syndrome is commonly accompanied by arthritis, which can be erosive, and by swollen/puffy hands and myositis. Pulmonary arterial hypertension is the major life-threatening complication in these patients and regular screening for this condition is essential.

Key words: anti-RNP antibodies, erosive arthritis, mixed connective tissue disease, myositis, overlap syndromes, Raynaud's

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(07)00110-6

doi:10.1016/j.berh.2007.10.002

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1037-1049, December 2007